ClinicalTrials.gg
RecruitingNCT07226583NEXTUpdated Nov 18, 2026

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

An interventional study of Standard-of-Care Guidance (SoC) and Usual Care (UC) in Type 1 Diabetes Mellitus and Exercise Physiology, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Stanford University · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 18, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Diabetes Mellitus, Type 1 by Stanford University — 4 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Stanford University.

Planned enrollment
19th of 28
20 · median 24
Started
2026
with 1 other
No phase
23 of 31
4 open now
Registered
29th of 31
by date

Among the 31 studies in Diabetes Mellitus, Type 1 by Stanford University, this one is the 19th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, and was the 29th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 31 studies in Diabetes Mellitus, Type 1 by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Diabetes Mellitus, Type 1 by Stanford University, or all of them as a file.
02

Study summary

This study evaluates a clinician-facing decision-support toolkit designed to assist adults with type 1 diabetes in preparing for moderate-intensity exercise. The netIOB \& Exercise Toolkit (NEXT) integrates recent glucose data and insulin delivery history to provide individualized suggestions regarding exercise timing, insulin adjustments, and carbohydrate intake.

Adults with type 1 diabetes will complete three supervised exercise sessions under different pre-exercise guidance approaches:

(A) published consensus-based standard-of-care guidance, (B) usual personal care routines, and (C) guidance informed by the NEXT Toolkit.

A healthy adult control group will complete a single supervised exercise session to provide comparative physiologic data.

Read the detailed description

People with type 1 diabetes frequently experience variable glucose responses before, during, and after physical activity, including exercise-associated hypoglycemia and the need for unplanned carbohydrate intake. Although consensus-based recommendations exist to guide exercise preparation, many individuals continue to rely on trial-and-error strategies that can be burdensome or difficult to generalize across activities.

This study evaluates the netIOB \& Exercise Toolkit (NEXT), a software-based, clinician-facing decision-support system intended to contextualize exercise preparation using recent continuous glucose monitoring (CGM) data and insulin delivery history. The Toolkit estimates net insulin-on-board relative to an individual's programmed basal insulin profile and presents structured, non-automated suggestions related to exercise timing, insulin target adjustments, and carbohydrate intake. All decisions remain under clinician and participant control.

The primary study population consists of adults with type 1 diabetes who complete three supervised, moderate-intensity exercise sessions in a randomized, three-period crossover design. Each session is conducted under a different pre-exercise strategy: consensus standard-of-care guidance, usual personal care routines, or guidance informed by the NEXT Toolkit. Sessions are separated by washout periods to minimize physiologic carryover, and glycemic, insulin delivery, and behavioral outcomes are assessed during exercise and for up to 48 hours post-exercise.

In addition, a healthy adult control group completes a single supervised exercise session without pre-exercise glucose or insulin management interventions. This group is included to provide comparative physiologic context for exploratory analyses.

Exploratory analyses will examine relationships between pre-exercise net insulin-on-board (netIOB) strata and glycemic, insulin, and treatment outcomes across exercise sessions. These analyses are intended to characterize patterns of response rather than to test formal efficacy hypotheses.

Participants in both the type 1 diabetes and healthy control groups will wear a commercially available continuous ketone monitoring (CKM) sensor (SiBio KS1) for exploratory data collection during exercise and defined post-exercise monitoring periods. CKM data are collected solely for research purposes, are not used to guide clinical or study-related decisions, and are not intended to evaluate device performance.

The NEXT Toolkit is classified as a non-significant risk, IDE-exempt investigational tool. Results from this pilot study are intended to inform future research design and the development of transparent, open-access methods for studying exercise physiology and glucose management in diabetes.

03

Conditions studied

  • Type 1 Diabetes Mellitus
  • Exercise Physiology

Keywords

  • Type 1 Diabetes
  • T1D
  • T1DM
  • Continuous Glucose Monitoring
  • Insulin Dosing
  • CGM
  • Insulin Pump
  • Exercise
  • carbohydrate Intake
  • closed-loop system
  • hybrid closed-loop
  • CKM
  • Continuous Ketone Monitoring
  • Glucose Metabolism
  • Ketone Metabolism
  • Exercise Metabolism
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria Inclusion Criteria: All Participants (Type 1 Diabetes and Healthy Control Groups)

  • Adults between the age of 18-60 years
  • Able to perform moderate intensity walking for 60 minutes (target 40-60% age-predicted maximal heart rate).
  • Willing and able to comply with study procedures, including supervised exercise visits and device wear
  • Able to provide written

Inclusion Criteria: Type 1 Diabetes Group Only

  • Clinical diagnosis of type 1 diabetes for >1 year, based on the investigator's clinical judgement
  • Current use of continuous subcutaneous insulin infusion with Tandem Control-IQ and a compatible continuous glucose monitor (CGM) for >1 month prior to enrollment
  • Stable insulin delivery regimen, with no planned changes to insulin pump settings or insulin dosing strategy during the study period
  • Consistent CGM use during the month prior to enrollment (>80% data availability)

Inclusion Criteria: Health Control Group Only

  • No diagnosis of diabetes or other disorders of glucose metabolism
  • Not using insulin or glucose-lowering medications

Exclusion Criteria Exclusion Criteria: All Participants

  • Intercurrent illness or medical condition that precludes safe participation in moderate-intensity exercise (e.g., unstable cardiopulmonary disease, uncontrolled arrhythmia, or uncontrolled hypertension), as previously assessed by the participant's primary care physician
  • Known coronary artery disease with symptoms limiting moderate physical activity, or history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the past 12 months
  • Pregnancy, lactation, or plans to become pregnant during the study period
  • Renal insufficiency with estimated \<45 mL/min/1.73 m², dialysis dependence, or adrenal insufficiency
  • Concurrent participation in another interventional drug or device study within 30 days prior to enrollment
  • Inability to comply with study procedures or safety requirements (e.g., inability to achieve target heart-rate zone, attend scheduled visits, or enable required device data access), or otherwise deemed unsuitable by the investigator

Exclusion Criteria: Type 1 Diabetes Group Only

  • Use of non-CSII insulin delivery, including long-acting injectable or inhaled insulin, during the study period
  • Use of medications with potential to substantially affect glycemia (e.g., SGLT-2 inhibitors, GLP-1 receptor agonists, or GIP agonists), unless on a stable regimen with no planned changes during the study
  • Use of systemic within 4 weeks prior to participation
  • History of severe hypoglycemia (requiring third-party assistance) or diabetic ketoacidosis within the prior 6 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Standard-of-Care (SoC)

    Participants follow consensus-based guidance for insulin and carbohydrate adjustments around exercise, as outlined in current international standards. These recommendations are applied by study staff in advance of the exercise session.

    Behavioral: Standard-of-Care Guidance (SoC) · Device: Continuous Glucose Monitoring · Device: Continuous Ketone Monitoring

  • Other
    Usual Care (UC)

    Participants use their own strategies for managing insulin and carbohydrate around exercise.

    Behavioral: Usual Care (UC) · Device: Continuous Glucose Monitoring · Device: Continuous Ketone Monitoring

  • Experimental
    netIOB & Exercise Toolkit (NEXT)

    Physicians receive personalized, algorithm-informed recommendations for exercise-related insulin and carbohydrate adjustments. Recommendations are generated using the investigational netIOB \& Exercise Toolkit based on CGM data, insulin history, and real-time inputs.

    Device: netIOB & Exercise Toolkit (NEXT) · Device: Continuous Glucose Monitoring · Device: Continuous Ketone Monitoring

  • Other
    Healthy Control

    Adults without diabetes complete one supervised moderate-intensity exercise session for physiologic comparison.

    Device: Continuous Glucose Monitoring · Device: Continuous Ketone Monitoring

Interventions

  • BehavioralStandard-of-Care Guidance (SoC)

    Study staff provide insulin and carbohydrate adjustment advice based on consensus exercise management guidelines (Moer et al., 2024), tailored to the planned activity.

  • BehavioralUsual Care (UC)

    Participants independently manage their insulin and carbohydrate decisions around exercise, using their routine practices without study-provided guidance.

  • DevicenetIOB & Exercise Toolkit (NEXT)

    An investigational software tool generates individualized insulin and carbohydrate adjustment recommendations before and after exercise using CGM data and recent insulin delivery. Study physicians review and relay these recommendations to participants.

  • DeviceContinuous Glucose Monitoring

    Continuous glucose monitoring using an FDA-cleared system (Dexcom G7) for research data collection during and after exercise. CGM data are used to assess glycemic responses and are not used to evaluate device performance or accuracy.

  • DeviceContinuous Ketone Monitoring

    A commercially available continuous ketone monitoring (CKM) device will be used for exploratory data collection during and after exercise. Ketone data are collected for research purposes only and are not used for clinical decision-making or to evaluate device performance.

06

What researchers measure

Primary outcomes

  1. Composite Score of Glycemic Safety and Carbohydrate Burden

    This composite outcome reflects glycemic risk during exercise and the subsequent post-exercise monitoring period. The score is based on a Magni risk-derived metric computed from continuous glucose monitoring (CGM) data, with the glycemic effects of rescue carbohydrate treatments removed to isolate underlying glycemic risk. Each evaluated timepoint is given a score ranging from 0 to 100, where lower scores indicate lower glycemic risk and higher scores indicate higher glycemic risk. Scores across the defined observation windows are summarized across intervention conditions.

    Time frame: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).

Secondary outcomes

  1. Percent-Based Continuous Glucose Monitor Metrics

    Assess standard continuous glucose monitoring (CGM) metrics during defined time windows relative to exercise (0-90 minutes, 0-6 hours, 6-24 hours, and 24-48 hours post-exercise). These include: * Percent Time in Range (TIR): 70-180 mg/dL * Percent Time Below Range (TBR): \<70 mg/dL and \<54 mg/dL * Percent Time Above Range (TAR): \>180 mg/dL and \>250 mg/dL

    Time frame: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).

  2. Glucose Concentration and Variability Metrics from Continuous Glucose Monitor

    Mean glucose level, glucose standard deviation (SD), and coefficient of variation (CV) will be calculated using CGM data collected over defined time periods relative to exercise. These metrics describe overall glycemic variability and will be used to assess the stability of glucose control following each intervention. Units of Measure: Mean glucose: mg/dL SD: mg/dL CV: %

    Time frame: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).

  3. Frequency of Hypoglycemic Events

    Number of hypoglycemic episodes per participant at thresholds of \<70 mg/dL and \<54 mg/dL, stratified by treatment arm. Events will be classified as treated or untreated.

    Time frame: Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise); total of 7.5 hours per visit (3 visits).

  4. Glucose Nadir Value

    Lowest glucose value (nadir mg/dl) recorded per participant during exercise period and 0-6 hours post-exercise, as measured by CGM.

    Time frame: Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise); total of 7.5 hours per visit (3 visits).

  5. Time to First Hypoglycemic Event

    Time (in minutes) from exercise start to the first hypoglycemic episode (\<70 mg/dL) for each participant.

    Time frame: Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise); total of 7.5 hours per visit (3 visits).

  6. Carbohydrate Consumption for Hypoglycemia Prevention/Treatment

    Quantify carbohydrate use related to exercise using: * Total grams of carbohydrate consumed * Number of carbohydrate treatment episodes * Categorization as prophylactic or reactive

    Time frame: Exercise (0 to 90 minutes); total of 1.5 hours per visit (3 visits).

  7. Total and Programmed Insulin Delivery

    Compare the total insulin delivered (actual) to the amount that would have been delivered based on the participant's pre-programmed basal rates. This includes both basal and bolus insulin.

    Time frame: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).

  8. Frequency of User-Initiated Pump Adjustments

    Number of times participants manually modified insulin delivery during the exercise period, including suspensions, temporary targets, exercise mode, or basal rate changes.

    Time frame: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).

  9. Duration of User-Initiated Pump Adjustments

    Cumulative duration of user-initiated pump modifications, including time spent in temporary targets, pump suspensions, and exercise modes.

    Time frame: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).

  10. Baseline and Peak Ketone Levels

    Baseline and peak ketone concentrations (mmol/L) measured using continuous ketone monitoring during the exercise period. Outcomes will be explored across pre-exercise strategies in participants with type 1 diabetes and relative to healthy control participants.

    Time frame: Baseline (immediately prior to exercise) and Exercise (0 to 90 minutes from exercise).

  11. Ketone Exposure (AUC) During and After Exercise

    Ketone exposure quantified as area under the curve (AUC) from continuous ketone monitoring during exercise (0-90 minutes from exercise start) and early post-exercise (0-6 hours after exercise). Outcomes will be explored across pre-exercise strategies in participants with type 1 diabetes and relative to healthy control participants.

    Time frame: Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise) per visit.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant-level data will be shared, including: Continuous glucose monitoring (CGM) metrics from the Dexcom G7 (e.g., time in range, time below/above range, mean glucose, glucose variability) Carbohydrate treatment data (timing, amount, type) Insulin delivery data (e.g., pump settings, suspensions, automated adjustments) Demographic information (e.g., age range, sex, diabetes duration) IPD that will not be shared includes: Direct identifiers (e.g., names, exact dates of birth, addresses) Free-text responses or notes containing potentially identifiable information Any raw data not essential to the reported outcomes or secondary analyses

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available beginning 18 months after article publication and ending 5 years following article publication.

Access criteria: Proposals should be directed to dessi@stanford.edu. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for May 2027, 6 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 6 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Oct 2026 → Nov 2026, primary completion Feb 2027 → May 2027 and completion Feb 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2025
First posted
Nov 10, 2025
StartActual
Nov 6, 2026was Oct 2026
Primary completionEst.
May 2027was Feb 2027
CompletionEst.
May 2027was Feb 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
Stanford University is now Recruiting
Nov 18, 2026
Start date
Oct 2026→Nov 6, 2026 (actual)
Nov 18, 2026
Primary completion
Feb 2027→May 2027
Nov 18, 2026
Study completion
Feb 2027→May 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    Stanford University is now Recruiting
    Start date Oct 2026→Nov 6, 2026 (now actual)
    Primary completion Feb 2027→May 2027
    Study completion Feb 2027→May 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07226583
Collaborators
University College Dublin, The Leona M. and Harry B. Helmsley Charitable Trust
Responsible party
Rayhan A. Lal (Assistant Professor of Medicine & Pediatrics, Stanford University) — Principal investigator
First posted
Nov 10, 2025
Start date
Nov 6, 2026
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Dessi Zaharieva, PhD
Contact
dessi@stanford.edu
628-238-9420
Ryan Kingman, BS
Contact
rkingman@stanford.edu
650-736-4417
Rayhan Lal, MD
principal investigator · Stanford University
Dessi dessi@stanford.edu, PhD
study director · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion